Combining Antibody–Drug Conjugates with Next-Generation Bispecific Immuno-Oncology Therapies

An overview of how future cancer care may combine antibody–drug conjugates with immuno-oncology agents to potentially replace older chemotherapy approaches.

■ Antibody–drug conjugates and immunotherapy
- Described as “smart chemotherapy”
- Positioned to be combined with immuno-oncology and oncology products
■ First- and next-generation immuno-oncology agents
- First generation: PD-1 or PD-L1 inhibitors already in use with a substantial impact
- Next generation: bispecific agents targeting PD-1 or PD-L1 and VEGF
■ Rationale and scope
- Other bispecific immune agents are mentioned
- This PD-1/PD-L1 × VEGF type is highlighted for certain tumors when combined with antibody–drug conjugates
- Compared with current first-generation PD-1 or PD-L1 therapies

Viewers interested in the evolving direction of cancer therapy can gain a concise overview of how antibody–drug conjugates and bispecific immuno-oncology approaches may be positioned relative to first-generation PD-1/PD-L1 therapies.